Oppenheimer analyst Leland Gershell downgrades $ESSA Pharma (EPIX.US)$ to a hold rating.
According to TipRanks data, the analyst has a success rate of 37.3% and a total average return of 3.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $ESSA Pharma (EPIX.US)$'s main analysts recently are as follows:
Essa Pharma has decided to cease all development of masofaniten after a predetermined futility analysis indicated the candidate did not achieve the desired efficacy profile in the Phase 2 enzalutamide combination study. The company is now initiating a strategic process to explore options that would best enhance shareholder value, details of which are anticipated.
Essa Pharma has halted all masofaniten programs after an interim analysis from its Phase 2 trial, which did not demonstrate any advantage of combining maso with enza over enza alone in treating metastatic castration-resistant prostate cancer. Analysts note the update is unfortunate, but commend the company for its swift action to cease these programs and consider strategic alternatives. Concerns have been raised regarding the company's future direction and the absence of additional assets at various stages of development.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Leland Gershell下調$ESSA Pharma (EPIX.US)$至持有評級。
根據TipRanks數據顯示，該分析師近一年總勝率為37.3%，總平均回報率為3.4%。
此外，綜合報道，$ESSA Pharma (EPIX.US)$近期主要分析師觀點如下：
essa pharma決定在預定的無效性分析表明該候選藥在第2期恩曲唑胺聯合研究中未達到期望的療效特徵後，停止所有masofaniten的開發。公司現在正在啓動戰略流程，探討最能增強股東價值的選擇，具體細節將在之後公佈。
essa pharma在其第2期試驗的中期分析後停止了所有masofaniten項目，該試驗未顯示將maso與enza聯合治療轉移性去勢抵抗性前列腺癌優於單獨使用enza。分析師指出更新消息令人遺憾，但讚揚該公司迅速採取措施終止這些項目並考慮戰略選擇。有關公司未來方向及在發展各階段缺乏額外資產的擔憂已經被提出。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
